Citalopram for the Prevention of Depression and Its Consequences in HIV-Hepatitis C Coinfected Individuals Initiating Pegylated Interferon/Ribavirin Therapy: A Multicenter Randomized Double-Blind Placebo-Controlled Trial

Conclusions: A strategy of prophylactic citalopram compared to treatment of emergent depression was not associated with higher adherence or a reduction in treatment-limiting depression nor did it significantly reduce depressive symptoms among HIV-HCV coinfected persons during treatment for HCV. Content Type Journal ArticleCategory Original ArticlePages 161-175DOI 10.1310/hct1504-161Authors Marina B. Klein, Division of Infectious Diseases/Chronic Viral Illness Service, Department of Medicine, Royal Victoria Hospital, McGill University Health Centre, Montréal, Québec, CanadaTerry Lee, Canadian HIV Trials Network, Vancouver, British Columbia, CanadaMarie-Josée Brouillette, Division of Infectious Diseases/Chronic Viral Illness Service, Department of Medicine, Royal Victoria Hospital, McGill University Health Centre, Montréal, Québec, CanadaNancy L. Sheehan, Division of Infectious Diseases/Chronic Viral Illness Service, Department of Medicine, Royal Victoria Hospital, McGill University Health Centre, Montréal, Québec, CanadaSharon Walmsley, Canadian HIV Trials Network, Vancouver, British Columbia, CanadaDavid K. Wong, University Health Network, University of Toronto, Toronto, Ontario, CanadaBrian Conway, Vancouver Infectious Diseases Research and Care Centre, Vancouver, British Columbia, CanadaMark Hull, BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, CanadaCurtis Cooper, Canadian HIV Trials Network, Vancouver, British Columbia, CanadaShariq Haidar, Mc...
Source: HIV Clinical Trials - Category: Infectious Diseases Tags: HIV Clinical Trials Source Type: research